Clinical Trial of WBC100 Capsule in Relapsed/Refractory Acute Myeloid Leukemia

The goal of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of WBC100 capsules in patients with relapsed or refractory acute myeloid leukemia (R/R AML). The main questions it aims to answer are: * What is the safety and tolerability profile of WBC100 in R/R AML patients? * Can WBC100 effectively induce remission in R/R AML patients? Participants will: * Take WBC100 capsules orally once daily in 28-day treatment cycles; * Undergo regular safety assessments, including adverse event monitoring and laboratory tests; * Provide blood sa

Trial Details

NCT ID
NCT07014449
Phase
PHASE1
Sponsor
Hangzhou Weben Pharma Co., Ltd
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • WBC100 QD
Locations (sample)
  • Hangzhou, Zhejiang, China|30.29365,120.16142

Key Eligibility Criteria

  • 1\. Signed informed consent and compliance with study procedures;
  • 2\. Male or female participants aged ≥18 years at the time of consent;
  • 3\. Diagnosis of relapsed or refractory acute myeloid leukemia (R/R AML) according to the 2016 World Health Organization (WHO) classification;
  • 4\. ECOG PS 0-2;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →